Hvin和Ki-67蛋白在胆管癌组织中表达的意义

目的 探讨Livin和Ki-67蛋白在胆管癌组织中的表达及两者之间的关系和临床意义.方法 采用SP法检测2002年1月至2003年12月中国医科大学附属盛京医院手术切除的55例胆管癌组织和12例慢性胆管炎组织中Livin和Ki-67蛋白的表达,并分析这两种蛋白与胆管癌临床病理特征的关系.应用Spearman等级相关分析、χ2检验和t检验对结果进行分析.结果 Livin蛋白在胆管癌标本中的阳性表达率为71%(39/55),明显高于慢性胆管炎标本的0(0/12)(χ2=20.361,P<0.01);Livin蛋白的表达受胆管癌患者的分化程度和淋巴结转移影响(χ2=4.193,4.245,P<0.05).Ki-67蛋白在胆管癌标本中的阳性表达率为96%(53/55).临床Ⅰ、Ⅱ、Ⅲ、Ⅳ期患者Ki-67标记指数分别为22%±16%、33%±12%、43%±15%、49%±10%,Ⅱ、Ⅲ、Ⅳ期与Ⅰ期比较差异有统计学意义(t=2.307,2.871,3.957,P<0.05);有无局部淋巴结转移的患者Ki-67标记指数分别为43%±13%、34%±16%,两者比较差异有统计学意义(t=2.334,P<0.05).胆管癌组织中Livin蛋白的表达与Ki-67标记指数呈正相关(r=0.502,P<0.01).结论 Livin蛋白在胆管癌的发生、发展中起重要作用,并且与胆管癌增殖活性相关,两者结合可作为胆管癌恶性程度和判断预后的标准.     

胰腺类癌一例

患者女性,73岁.以上腹部间断疼痛8年,加重半个月于2008年3月7日入我院.发病以来无发热、黄疽、腹泻、恶心、呕吐,有黑便病史.既往高血压病史5年,心脏病史8年,自用药物治疗.体检:皮肤巩膜无黄染,腹软无压痛,未触及肿物.     

Hvin和Ki-67蛋白在胆管癌组织中表达的意义

Objective To investigate the relationship between Livin and Ki-67 proteins, and the expres-sion and clinical significance of Livin and Ki-67 proteins in cholangiocarcinoma. Methods Fifty-five samples of cholangiocarcinoma tissue were collected in Shengjing Hospital from January 2002 to December 2003. The expres-sion of Livin and Ki-67 proteins in the 55 samples of cholangiocarcinoma tissue and 12 samples of chronic cholan-gitis tissue were detected by immunohistochemical assay. The relationship between the expression of Livin and Ki-67 proteins and the clinicopathological parameters of cholangiocarcinoma was analyzed. The results were analyzed by Spearman rank correlation coefficient, chi-square test and t test. Results The positive expression rate of Livin protein in cholangiocarcinoma was 71% (39/55), which was significantly higher than 0 (0/12)in chronic cholan-girls tissue (χ2=20.361, P<0.01). The expression of Livin protein was influenced by the differentiation of cholangiocarcinoma and the lymph node metastasis (χ2=4.193, 4.245, P <0.05). The positive expression rate of Ki-67 protein was 96% (53/55) in cholangiocarcinoma. The label index of Ki-67 in patients in clinical stage Ⅰ,Ⅱ,Ⅲ,Ⅳ,were 22%±16%, 33%±12%, 43%±15%, and 49%±10%, respectively. There was signifi-cant difference in the label index of Ki-67 between patients in clinical stage Ⅰ and those in clinical stages Ⅱ, Ⅲ,Ⅳ(t=2.307, 2.871, 3.957, P<0.05). The label index of Ki-67 was 43%±13 % in patients with local lymph node metastasis, and 34%±16% in patients without local lymph node metastasis, with statistical difference between the 2 groups (t=2.334, P<0.05). The expression of Livin protein in cholangiocarcinoma was positively correlated with the label index of Ki-67 (r=0.502, P<0.01). Conclusions Livin protein plays an important role in the pathogenesis and development of eholangiocarcinoma, and it also has correlation with the proliferating activity of cholangiocarcinoma cells. Combined detection of the expression of Livin and Ki-67 proteins may be helpful in judging the malignancy of cholangiocarcinoma and determining the prognosis of patients.     

Hvin和Ki-67蛋白在胆管癌组织中表达的意义

Objective To investigate the relationship between Livin and Ki-67 proteins, and the expres-sion and clinical significance of Livin and Ki-67 proteins in cholangiocarcinoma. Methods Fifty-five samples of cholangiocarcinoma tissue were collected in Shengjing Hospital from January 2002 to December 2003. The expres-sion of Livin and Ki-67 proteins in the 55 samples of cholangiocarcinoma tissue and 12 samples of chronic cholan-gitis tissue were detected by immunohistochemical assay. The relationship between the expression of Livin and Ki-67 proteins and the clinicopathological parameters of cholangiocarcinoma was analyzed. The results were analyzed by Spearman rank correlation coefficient, chi-square test and t test. Results The positive expression rate of Livin protein in cholangiocarcinoma was 71% (39/55), which was significantly higher than 0 (0/12)in chronic cholan-girls tissue (χ2=20.361, P<0.01). The expression of Livin protein was influenced by the differentiation of cholangiocarcinoma and the lymph node metastasis (χ2=4.193, 4.245, P <0.05). The positive expression rate of Ki-67 protein was 96% (53/55) in cholangiocarcinoma. The label index of Ki-67 in patients in clinical stage Ⅰ,Ⅱ,Ⅲ,Ⅳ,were 22%±16%, 33%±12%, 43%±15%, and 49%±10%, respectively. There was signifi-cant difference in the label index of Ki-67 between patients in clinical stage Ⅰ and those in clinical stages Ⅱ, Ⅲ,Ⅳ(t=2.307, 2.871, 3.957, P<0.05). The label index of Ki-67 was 43%±13 % in patients with local lymph node metastasis, and 34%±16% in patients without local lymph node metastasis, with statistical difference between the 2 groups (t=2.334, P<0.05). The expression of Livin protein in cholangiocarcinoma was positively correlated with the label index of Ki-67 (r=0.502, P<0.01). Conclusions Livin protein plays an important role in the pathogenesis and development of eholangiocarcinoma, and it also has correlation with the proliferating activity of cholangiocarcinoma cells. Combined detection of the expression of Livin and Ki-67 proteins may be helpful in judging the malignancy of cholangiocarcinoma and determining the prognosis of patients.     

病毒性肝炎合并非酒精性脂肪肝的临床与病理分析

目的 探讨慢性乙型肝炎(CHB)合并非酒精性脂肪肝(NAFLD)的临床与病理关系特征.方法 回顾性调查2007年1月至2009年12月肝活组织检查确诊的慢性乙型肝炎患者合并非酒精性脂肪肝的患病率.剔除合并慢性丙型肝炎(HCV)和人类免疫缺陷病毒等感染及酒精性、药物性脂肪肝.比较临床资料完整的肝脂肪变患者与其性别、年龄相配的无脂肪变的患者的临床病理特征.结果 522例慢性乙型肝炎合并非酒精性脂肪肝患病率为17.82%(93/522),研究期间2007年患病率为18.54%,2008年患病率为17.99%,2009年患病率为16.41%,有逐年减少的趋势.与无脂肪肝的45例乙型肝炎患者相比,合并非酒精性脂肪肝者的49例空腹血糖、甘油三酯、总胆固醇水平明显升高(t=2.63、3.36、3.54,P＜0.05).两组患者ALT、AST、谷氨酰转肽酶(GGT)、碱性磷酸酶(ALP)和总胆红素(T-Bil)差异均无统计学意义(P＞0.05).肝脏病理分级和分期组织学显示炎症(G≥2)或/和纤维化(S≥2)的CHB216例合并肝脂肪变的31例(14.35%).而肝损伤较轻的308例合并肝脂肪变的62例(20.26%),差异无统计学意义(P＞0.05).结论 慢性乙型肝炎合并非酒精性脂肪肝变常见,3年来没有增多趋势,主要与糖脂代谢紊乱有关.不同程度肝损伤的患者肝脂肪变率差异无统计学意义,肝损伤较重的患者中有大约15%的患者合并肝脂肪变,可能影响抗病毒治疗的效果与治疗方案的选择,应该予以重视.     

HGF抑制人肝癌细胞增殖作用的实验研究

目的 探讨肝细胞生长因子(HCF)对人肝癌细胞增殖的作用及其机制.方法 通过溴脱氧尿核苷(BrdU)细胞增殖酶联免疫实验观察HGF对人肝癌细胞株HepG2细胞的增殖作用,采用Western印迹和RT-PCR法检测p27、p21和p18基因的表达.将反义p27表达质粒转染HepG2细胞获得稳定转染的p27低表达HepG2细胞,观察HGF对该转染细胞增殖的影响.结果 HCF对HepG2细胞的增殖具有浓度依赖性和时间依赖性抑制作用,HGF明显促进HepG2细胞p27蛋白和mRNA表达,但对p21和p18的表达则无影响.HGF对反义p27稳定转染的HepG2细胞无增殖抑制作用.结论 HGF对HepG2细胞具有明显的增殖抑制作用,其作用机制与上调p27表达密切相关.     

Ad-PUMA联合SU5416对裸鼠胰腺癌生长和转移的抑制作用

目的：研究重组腺病毒（Ad）-PUMA联合SU5416对裸鼠胰腺癌生长和转移的抑制作用。方法：建立裸鼠胰腺癌AsPC-1细胞株原位移植瘤模型,将胰腺癌裸鼠随机分为4组,于模型的第14天,分别自腹腔注射生理盐水100μL（对照组,n=8）、Ad—PUMA3×10^8pfu／100μL（PUMA组,n=10）、SU5416制剂16mg／kg（SU5416组,n=9）和Ad—PUMA＋SU54163×10^8pfu／100μL＋SU541616mg／kg（联合组,n=10）。治疗2周后处死裸鼠,剖腹测量原位肿瘤瘤重、抑瘤率、肿瘤微血管密度、胰腺癌细胞凋亡指数,同时观察腹膜、肝脏及毗邻脏器转移和腹水情况。结果：对照组、PUMA组、SU5416组、联合组诱发肿瘤瘤重分别为（0．72±0．08）、（0．48±0．06）、（0．52±0．07）、（0．21±0．04）g,抑瘤率分别为0、28％、34％、71％,肿瘤微血管密度分别为21．4±2．7、20．2±2．5、8．3±1．6、3．8±1．0,凋亡指数分别为（2．7±1．8）、（13．7±3．4）、（5．5±3．7）、（20．6±8．6）％,腹膜转移率分别为87％、70％、33％、10％,肝转移率分别为75％、50％、22％、0,联合组与对照组比较差异有统计学意义（P均〈0．05）。结论：AdPUMA联合SU5416具有协同抗胰腺癌作用。     

HGF下调Skp2表达抑制人肝癌细胞增殖的实验研究

目的：探讨肝细胞生长因子(HGF)对人肝癌细胞增殖的作用及其机制。方法：人肝癌细胞株HepG2用于实验。通过BrdU细胞增殖酶联免疫实验观察HGF对细胞增殖的作用,采用Western印迹和RT-PCR法检测HGF对S期激酶结合蛋白2(Skp2)表达的影响。将Skp2真核细胞重组表达质粒转染HepG2细胞并获得稳定转染的过表达Skp2的HepG2细胞,观察HGF对该转染细胞增殖的影响。结果： HGF对HepG2细胞的增殖具有浓度依赖性和时间依赖性的抑制作用;HGF明显抑制HepG2细胞表达Skp2蛋白和mRNA。但HGF对过表达Skp2的HepG2细胞无增殖抑制作用。结论：HGF对HepG2细胞具有明显的增殖抑制作用,其作用机制与下调Skp2表达密切相关。     

人手皮肤环层小体分布的形态学研究

 目的研究S-100 蛋白和髓鞘碱性蛋白（MBP）在人手指皮肤环层小体上的表达情况。方法采用SP免疫组化方法检
测S-100 蛋白和MBP 在人手指皮肤环层小体上的表达。结果真皮乳头嵴存在于表皮嵴下,与指纹并行排列。环层小体广泛
分布在真皮网织层和皮下组织层。皮神经和感觉小体分布在血管和汗腺附近。结论S-100 蛋白和MBP免疫过氧化物酶染色
标记施万细胞具有特异性。掌指关节区、鱼际区的环层小体平均数量偏高。     

改良法白内障囊外摘除术的临床效果观察

目的 观察改良法白内障囊外摘除术的临床效果.方法 将96名年龄相关性白内障(Ⅴ级核)分为3组,一组采用传统白内障囊外摘除加人工晶状体植入术治疗;一组采用改良法白内障囊外摘除加人工晶状体植入术治疗,即术中应用隧道切口、连续环形撕囊及水分离;另一组采用超声乳化白内障摘除加人工晶状体植入术治疗.比较三组患者的平均手术时间、角膜内皮细胞损失率、术中并发症发生率及术后1年的后发性白内障发生率.结果 传统囊外摘除术组患者的平均手术时间、角膜内皮细胞损失率、术中并发症发生率及术后1年的后发性白内障发生率分别为(15.0±6.32)min、(14.18±5.43)%、5.0%(2/40)、7.14%(2/28);改良囊外摘除术组则分别为(8.0±4.71)min、(9.58±6.34)%、2.38%(1/42)、3.7%(1/27);超声乳化组分另为(6.0±3.46)min、8.35±5.83%、4.35%(2/46)、5.56%(2/36).手术时间组间差异均有统计学意义,传统囊外摘除术组的手术后角膜内皮细胞丢失率与其他二组的差异具有统计学意义,其他二组间差异无统计学意义.结论改良法囊外摘除术能缩短手术时间、提高手术安全性、减少术中术后并发症的发生.